NCT05652907终止2 期
A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients With Chronic Widespread Musculoskeletal Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome (Disorder)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 4
- 主要终点
- Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity
研究概览
简要总结
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of idiopathic MCAS as per the global consensus diagnostic criteria
- •Adults with widespread chronic pain (in three or more body regions);
- •Chronic pains of intensity greater than or equal to 4.0 but less than or equal to 9.0 on a Numeric Pain Rating Scale, symptom duration of more than 6 months;
- •Subject agrees to use only acetaminophen (up to 1000 mg per dose and not to exceed 3000 mg/day) or diphenhydramine (up to 300 mg/day) as rescue medication for chronic widespread musculoskeletal nociplastic pains throughout the trial;
- •The subject is willing to maintain current activity and exercise levels throughout the study;
- •During the study, the subject agrees not to initiate or change any non-pharmacologic interventions (including chiropractic care, physical therapy, psychotherapy, and massage therapy). Any ongoing non-pharmacologic intervention must be stable for at least 4 weeks before screening and should be continued for the duration of the study;
排除标准
- •The subject has pain that cannot be clearly differentiated from or that could interfere with the assessment of chronic musculoskeletal nociplastic pain secondary likely to idiopathic MCAS (post-herpetic neuralgia, traumatic injury, prior surgery, complex regional pain syndrome);
- •Adults with chronic cancer pain;
- •Adults with inflammatory connective tissue disorder or rheumatological disorder-related pain, for example rheumatoid arthritis;
- •Adults with focal musculoskeletal pain;
- •Adults with skin diseases (chronic urticaria, pemphigus, lupus, rosacea etc.);
- •Adults with endocrinological disorders (acute hypothyroidism, acute adrenal insufficiency etc.);
- •Adults with systemic gastrointestinal conditions (Inflammatory bowel disorders);
- •Significant psychological comorbidities: PHQ-9 score greater than 20; and GAD-7 score greater than 15 (indication of severe anxiety that could interfere with accurate logging of pain ratings);
- •Current or recent (within 12 months of screening) history of a substance use disorder including cannabinoid or alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5);
- •Subject has neurologic disorder unrelated to chronic widespread musculoskeletal nociplastic pains (phantom limb from amputation, vitamin B12 deficiency, chronic inflammatory demyelinating polyneuropathy), circulatory disorder (peripheral artery disease), a skin condition in the area of neuropathy that could alter sensation (plantar ulcer), or other painful conditions (arthritis) that could interfere with reporting of pain due to chronic widespread musculoskeletal nociplastic pains;
- •Current severe or uncontrolled major depressive disorder or anxiety disorders. Mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study. Stable doses of SSRIs are allowed for the treatment of depression if the dose is stable for 60 days before Screening Visit;
- •Subject has a history of suicide attempt or suicidal behaviour within the last 12 months or has suicidal ideation within the previous 12 months or who is at significant risk to commit suicide, as judged by the Investigator at Screening and/or Randomization Visit;
- •Patients with active malignancy or history of malignancy, except for basal cell or squamous cell carcinoma and actinic keratosis. Basal cell carcinoma and small squamous cell carcinoma of the skin which have been excised according to guidelines within the last 5 years or in situ cervical carcinoma that has been fully treated and shows no evidence of recurrence are allowed;
- •Individuals with generalized joint hypermobility secondary to hereditary connective tissue disorders like Ehlers Danlos Syndrome;
- •Individuals with high baseline serum tryptase levels suggestive of Primary or Secondary MCAS (defined as above the normal range of 2.2 to 13.2 µg/L).
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive placebo matched to 600 mg FSD201 tablets twice daily (BID) orally from Day 0 to Day 56.
干预措施: Placebo (Drug)
FSD201
Experimental
Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally from Day 0 to Day 56.
干预措施: FSD201 (Drug)
结局指标
主要结局
Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity
时间窗: Day 28
Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity score measured by an 11-point numerical pain rating scale (NPRS). NPRS is an 11-point scale from 0 to10 where the higher number indicates worse pain. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28
Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity
时间窗: Day 28
Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity score measured by an 11-point numerical pain rating scale (NPRS). NPRS is an 11-point scale from 0 to10 where the higher number indicates worse pain. Averages will be calculated as follows: Baseline: calculated weekly average from Day -7 to Day -1 Day 28: calculated weekly average from Day 22 to Day 28
次要结局
- Percentage of subjects achieving ≥30% reduction in Numerical Pain Rating Scale (NPRS) score at the end of treatment with FSD201 at the end of treatment with FSD201(Day 28, Day 56)
- Change in the PROMIS Fatigue- SF 8a(Day 56)
- Reduction of plasma serum mast cell tryptase, IL-6, and IL-1beta during FSD201 treatment(Day 14, Day 28 and Day 56)
- Change in Patient Global Impression of Change (PGIC)(Day 28, Day 56)
- Change or reduction in patient average daily NPRS(Day 56)
- Percentage of subjects achieving ≥30% reduction in NPRS score(Day 28, Day 56)
- Change in Daily Sleep Interference Scale (DSIS)(Day 28, Day 56)
- Percentage of subjects achieving ≥50% reduction in NPRS(Week 1 to Week 8)
- Total amount of rescue medication used(Day 0 to Day 56)
- Incidence and severity of treatment-emergent adverse events (TEAEs)(Day 0 to Day 56)
- Incidence and severity of treatment-emergent changes in laboratory values(Day 56)
- Change from baseline in sitting blood pressure at each in-patient visit(Day 14, Day 28, Day 56)
- Change from baseline in body temperature at each in-patient visit(Day 14, Day 28, Day 56)
- Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance- Short Form (SF) 8a(Day 56)
- Change in the PROMIS Pain Interference- SF 8a score(Day 56)
- Change in the PROMIS General Life Satisfaction- SF 5a(Day 56)
- Change from baseline in oxygen saturation at each in-patient visit(Day 14, Day 28, Day 56)
- Change in pain intensity on the NPRS from baseline to each week of treatment(Day 0 to Day 56)
- Change from baseline in heart rate at each in-patient visit(Day 14, Day 28, Day 56)
- Change from baseline in breathing rate at each in-patient visit(Day 14, Day 28, Day 56)
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19COVID-19NCT04619706FSD Pharma, Inc.53
已完成
1 期
Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain EndpointsHealthyNCT02260947Pfizer20
已完成
2 期
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen ChallengeAsthmaNCT02422121Revalesio Corporation30
已完成
3 期
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma InjuriesAcute Blunt Soft Tissue Injuries/ContusionsNCT02290821Novartis215
已完成
3 期
A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle SorenessMuscle SorenessNCT02271854Novartis102